Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with its substantial $114.5 billion market capitalization, continues to dominate the cystic fibrosis (CF) treatment market while advancing a ...

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

continues to dominate the cystic fibrosis (CF) treatment market while advancing a promising pipeline of therapies for other serious diseases. The company, which maintains a strong financial health ...

When cystic fibrosis hits your lungs hard, hit back. Everything you need to know about getting your lungs back into shape is ...

A whole community of builders came on board to help turn a period house in south Dublin into a home away from home for the families of people with cystic fibrosis coming to the city for treatment.

The star joined forces with Dermot Bannon to achieve his goal of opening a home away from home for the families of cystic ...

Learn more about whether Natera, Inc. or Vertex Pharmaceuticals Incorporated is a better investment based on AAII's A+ ...

Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.

Ivacaftor in combination with the oral corrector VX-809 shows promise for the treatment of patients with the most common CF mutation, F508del. Phase 2 studies are continuing to determine the best ...

Vertex's lineup will look transformed in five years, and the company should continue performing well beyond that time. It's ...